Robert E. Sanchez
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Ryder System faces mixed analyst ratings and price target changes. Ryder System is experiencing a split in analyst sentiment this week. JP Morgan upgraded the stock to Overweight with a $298 price target, while Baird downgraded it to Neutral and Susquehanna lowered its target to $280. These moves reflect differing views on the company's outlook, with the average analyst target sitting at $291.22.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
TXN Announces Q3 Earnings Preview and Q4 2026 Dividend. Texas Instruments will report Q3 earnings next week, with analysts noting key metrics that could influence expectations. The board also declared a quarterly dividend for Q4 2026, adding to shareholder value. These developments keep the stock in focus for investors monitoring earnings performance and dividend policy.
Transaction History
| COR | ▲ Buy | Grant | 275 | — | 10/1/2026 | View on chart |
| R | ▲ Buy | Option Exercise | 104,390 | $8.0M | 2/24/2026 | View on chart |
| R | ▼ Sell | Tax Withholding | 62,611 | $14.1M | 2/24/2026 | View on chart |
| R | ▼ Sell | Open Market | 40,841 | $9.1M | 2/24/2026 | View on chart |
| R | ▼ Sell | Open Market | 676 | $151K | 2/24/2026 | View on chart |
| R | ▼ Sell | Open Market | 262 | $59K | 2/24/2026 | View on chart |
| R | ▼ Sell | Tax Withholding | 3,114 | $661K | 2/10/2026 | View on chart |
| R | ▼ Sell | Tax Withholding | 2,776 | $599K | 2/9/2026 | View on chart |
| R | ▼ Sell | Tax Withholding | 2,217 | $482K | 2/7/2026 | View on chart |
| R | ▲ Buy | Grant | 62,613 | $0 | 2/6/2026 | View on chart |
| R | ▼ Sell | Tax Withholding | 24,661 | $5.4M | 2/6/2026 | View on chart |
| R | ▲ Buy | Grant | 21,609 | $0 | 2/6/2026 | View on chart |
| TXN | ▲ Buy | Grant | 525 | $0 | 1/29/2026 | View on chart |
| R | ▼ Sell | Gift | 8,412 | $0 | 8/8/2025 | View on chart |
| R | ▼ Sell | Open Market | 1,245 | $227K | 7/29/2025 | View on chart |
| R | ▼ Sell | Open Market | 7,278 | $1.3M | 7/29/2025 | View on chart |
| R | ▼ Sell | Open Market | 3,657 | $653K | 7/29/2025 | View on chart |
| R | ▼ Sell | Open Market | 9,883 | $1.8M | 7/29/2025 | View on chart |
| R | ▲ Buy | Option Exercise | 104,439 | $5.8M | 7/28/2025 | View on chart |
| R | ▼ Sell | Tax Withholding | 60,313 | $11.0M | 7/28/2025 | View on chart |
| R | ▼ Sell | Open Market | 16,552 | $3.0M | 7/28/2025 | View on chart |
| R | ▼ Sell | Open Market | 5,511 | $1.0M | 7/28/2025 | View on chart |
| R | ▲ Buy | Option Exercise | 18,496 | $1.0M | 5/20/2025 | View on chart |
| R | ▼ Sell | Open Market | 18,496 | $2.9M | 5/20/2025 | View on chart |
| R | ▼ Sell | Tax Withholding | 3,534 | $559K | 2/11/2025 | View on chart |
| R | ▼ Sell | Tax Withholding | 3,111 | $490K | 2/10/2025 | View on chart |
| R | ▼ Sell | Tax Withholding | 2,775 | $438K | 2/9/2025 | View on chart |
| R | ▲ Buy | Grant | 84,794 | $0 | 2/7/2025 | View on chart |
| R | ▼ Sell | Tax Withholding | 33,396 | $5.3M | 2/7/2025 | View on chart |
| R | ▲ Buy | Grant | 17,729 | $0 | 2/7/2025 | View on chart |
| TXN | ▲ Buy | Grant | 614 | $0 | 1/27/2025 | View on chart |
| TXN | ▲ Buy | Option Exercise | 9,990 | $529K | 10/25/2024 | View on chart |
| TXN | ▼ Sell | Open Market | 9,990 | $2.1M | 10/25/2024 | View on chart |
| R | ▼ Sell | Gift | 8,265 | $0 | 8/19/2024 | View on chart |
| R | ▲ Buy | Option Exercise | 53,130 | $5.0M | 5/14/2024 | View on chart |
| R | ▼ Sell | Open Market | 26,579 | $3.4M | 5/14/2024 | View on chart |
| R | ▼ Sell | Open Market | 26,551 | $3.4M | 5/14/2024 | View on chart |
| R | ▲ Buy | Option Exercise | 18,303 | $1.7M | 5/13/2024 | View on chart |
| R | ▼ Sell | Open Market | 16,485 | $2.1M | 5/13/2024 | View on chart |
| R | ▼ Sell | Open Market | 1,818 | $231K | 5/13/2024 | View on chart |
| R | ▲ Buy | Option Exercise | 11,992 | $1.1M | 5/10/2024 | View on chart |
| R | ▼ Sell | Open Market | 11,992 | $1.5M | 5/10/2024 | View on chart |
| TXN | ▲ Buy | Option Exercise | 10,539 | $568K | 5/1/2024 | View on chart |
| TXN | ▼ Sell | Open Market | 10,539 | $1.8M | 5/1/2024 | View on chart |
| R | ▼ Sell | Tax Withholding | 3,554 | $423K | 2/12/2024 | View on chart |
| R | ▼ Sell | Tax Withholding | 3,540 | $415K | 2/11/2024 | View on chart |
| R | ▼ Sell | Tax Withholding | 3,116 | $365K | 2/10/2024 | View on chart |
| R | ▼ Sell | Tax Withholding | 33,535 | $3.9M | 2/9/2024 | View on chart |
| R | ▲ Buy | Grant | 22,199 | $0 | 2/9/2024 | View on chart |
| R | ▲ Buy | Grant | 85,132 | $0 | 2/9/2024 | View on chart |
| TXN | ▲ Buy | Grant | 686 | $0 | 1/25/2024 | View on chart |
| R | ▼ Sell | Gift | 3,150 | $0 | 11/20/2023 | View on chart |
| R | ▲ Buy | Option Exercise | 93,415 | $6.7M | 8/3/2023 | View on chart |
| R | ▼ Sell | Open Market | 62,621 | $6.3M | 8/3/2023 | View on chart |
| R | ▼ Sell | Open Market | 329 | $33K | 8/3/2023 | View on chart |
| R | ▼ Sell | Open Market | 415 | $42K | 8/3/2023 | View on chart |
| R | ▼ Sell | Open Market | 30,050 | $3.0M | 8/3/2023 | View on chart |
| R | ▼ Sell | Gift | 6,000 | $0 | 5/10/2023 | View on chart |
| R | ▼ Sell | Tax Withholding | 5,739 | $566K | 2/18/2023 | View on chart |
| R | ▼ Sell | Tax Withholding | 3,554 | $343K | 2/12/2023 | View on chart |
| R | ▼ Sell | Tax Withholding | 3,539 | $341K | 2/11/2023 | View on chart |
| R | ▼ Sell | Tax Withholding | 67,583 | $6.5M | 2/10/2023 | View on chart |
| R | ▲ Buy | Grant | 104,067 | $0 | 2/10/2023 | View on chart |
| R | ▲ Buy | Grant | 24,888 | $0 | 2/10/2023 | View on chart |
| TXN | ▲ Buy | Grant | 574 | $0 | 1/26/2023 | View on chart |
| R | ▲ Buy | Option Exercise | 88,225 | $5.1M | 10/31/2022 | View on chart |
| R | ▲ Buy | Option Exercise | 1,100 | $64K | 10/31/2022 | View on chart |
| R | ▼ Sell | Open Market | 88,225 | $7.1M | 10/31/2022 | View on chart |
| R | ▼ Sell | Open Market | 1,100 | $90K | 10/31/2022 | View on chart |
| TXN | ▲ Buy | Option Exercise | 12,299 | $542K | 5/13/2022 | View on chart |
| TXN | ▼ Sell | Open Market | 12,299 | $2.1M | 5/13/2022 | View on chart |
| R | ▼ Sell | Tax Withholding | 5,722 | $450K | 2/18/2022 | View on chart |
| R | ▼ Sell | Tax Withholding | 3,544 | $261K | 2/12/2022 | View on chart |
| R | ▼ Sell | Tax Withholding | 26,496 | $1.9M | 2/11/2022 | View on chart |
| R | ▲ Buy | Grant | 67,353 | $0 | 2/11/2022 | View on chart |
| R | ▲ Buy | Grant | 28,264 | $0 | 2/11/2022 | View on chart |
| R | ▼ Sell | Tax Withholding | 1,900 | $138K | 2/8/2022 | View on chart |
| TXN | ▲ Buy | Grant | 572 | $0 | 1/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects
Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects. Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.